We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Pinpoints Cause of Brain Injury in Newborns

By LabMedica International staff writers
Posted on 05 Feb 2024
Print article
Image: Blood test could reveal cause of brain injury in newborn babies (Photo courtesy of Imperial College)
Image: Blood test could reveal cause of brain injury in newborn babies (Photo courtesy of Imperial College)

Hypoxic-Ischemic Encephalopathy (HIE), also known as birth asphyxia, is a brain injury that occurs when a newborn's brain does not receive sufficient oxygen either before or just after birth. This condition is a major cause of death and disability in full-term babies worldwide, impacting about three million infants annually. Brain damage from oxygen deprivation can develop over a period ranging from hours to months, potentially impacting various brain areas and leading to diverse neurodisabilities such as cerebral palsy, epilepsy, and sensory impairments like deafness or blindness. South Asia, especially India, bears the brunt of this issue, with 60% of global HIE-related fatalities occurring in the country. Now, a blood test can pinpoint the underlying cause of brain injury in newborns and assist in making informed treatment choices.

In a study of infants with HIE, researchers from Imperial College London (London, UK) discovered that blood-based gene expression patterns can indicate the injury's origin and predict the infant's likelihood of responding to cooling treatment, a common method for treating brain injuries in babies. This advancement could pave the way for a simple blood test that rapidly diagnoses brain injuries in newborns, aiding in treatment decisions. The research included babies from both low and middle-income countries (LMICs) and high-income countries (HICs), revealing a stark contrast in gene expression between these groups, suggesting differing causes of brain injury.

Previous research, primarily in HICs, has shown that whole-body cooling can enhance recovery prospects for babies with HIE. This has led to its widespread adoption as standard practice in many HICs and some hospitals in South Asia. However, the most extensive study of its kind in LMICs, conducted by Imperial College London and its partners in India, Bangladesh, and Sri Lanka, had previously found that whole-body cooling might actually worsen outcomes and increase mortality risks in babies with HIE in these regions. The new study sheds light on why babies from different regions respond differently to cooling treatment and holds the potential for the development of a simple blood test to identify which infants will benefit from it. The research, a collaboration between Imperial College London and its South Asian partners, involved 35 Italian (a HIC) and 99 South Asian (from LMICs) newborns with HIE. Blood samples were collected soon after birth, and the infants were evaluated medically at 18 months.

About half of the babies in the South Asian group either passed away or developed severe disabilities, compared to a quarter in the Italian group. The researchers analyzed the correlation between gene expression at birth and outcomes at 18 months in both groups. They identified 1793 significant genes linked to adverse outcomes in the HIC group and 99 in the South Asian group, with only 11 significant genes common to both groups, but expressed differently. The researchers emphasized that these differences are not due to ethnic factors but rather socioeconomic ones. The type of chronic brain injury common in LMICs can also be found in impoverished areas of HICs. Conversely, in wealthier regions of LMICs, one might find more cases of acute brain injury, similar to those typically seen in HICs in this study.

“The key for clinicians, anywhere in the world, is to be able to identify which type of brain injury they are dealing with as soon as possible – and that’s something we’re currently working on,” said lead investigator, Professor Sudhin Thayyil from the Department of Brain Sciences at Imperial College London.

Related Links:
Imperial College London

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Uric Acid and Blood Glucose Meter
URIT-10
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.